Drugs / pyronaridine-artesunate
pyronaridine-artesunate
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05633420 | Jul → Sep 2022 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02389439 | Mar → Dec 2015 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05192265 | May 2019 → Dec 2020 | Plasmodium falciparum malaria | University of Ibadan | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04783051 | May 2021 → Jun 2022 | Plasmodium falciparum malaria | University of Kinshasa | Completed | No outcome recorded |
| Phase 3 | NCT02411994 | Oct 2015 → Aug 2017 | malaria | Royal Tropical Institute | Completed | No outcome recorded |
| Phase 3 | NCT00440999 | Mar 2007 → Apr 2008 | Plasmodium vivax malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 3 | NCT00422084 | Jan 2007 → Apr 2008 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 3 | NCT00403260 | Jan 2007 → Oct 2008 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07060794 | Jun 2026 → Jun 2028 expected | Plasmodium vivax malaria | Menzies School of Health Research | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03201770 | Jun 2017 → Apr 2019 | Plasmodium falciparum malaria | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01523002 Comparator | Jan → Jul 2012 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pyronaridine-artesunate | “BACKGROUND: Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine-artesunate (PA) paediatric granules in children from...” PMID 38418982 ↗ Feb 202410“Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)” NCT04783051 ↗ “the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg)” NCT00440999 ↗ |
| Known as | Artesunate-pyronaridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07060794 ↗ |
| Known as | Pyramax | “Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)” NCT04783051 ↗ |
| Modality | Other / unclassified | “Pyronaridine-artesunate is a novel artemisinin-based combination therapy.” PMID 29764419 ↗ May 2018 |
| Route | Oral | “Patients will be randomised in a 2:1 ratio to receive either oral PA (180:60mg tablets)” NCT00403260 ↗ |